Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
ASCO 2025 preview – late-breakers in focus
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
Protagonist Verifies Takeda’s interest
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
